GHK-Cu

Healing & Recovery

Also known as: GHK-Cu, Copper peptide, Glycyl-L-histidyl-L-lysine copper

Copper PeptidesResearch phase: Limited human trialsRegulatory: Not FDA-approved as a drug; widely available in cosmetic formulations; injectable form available as a research peptide.

Mechanism

GHK-Cu is a naturally occurring copper-binding peptide found in human blood that declines significantly with age. It acts as a powerful signal to your body to repair and regenerate tissue, stimulating collagen production, wound healing, and skin remodeling while also reducing inflammation and scar tissue formation. It is widely used in skincare for anti-aging and is also being studied for hair growth, lung repair, and tissue regeneration.

Technical detail

GHK-Cu is a tripeptide-copper(II) complex (glycyl-L-histidyl-L-lysine:Cu2+) that functions as a pleiotropic signaling molecule modulating over 4,000 human genes, including upregulation of collagen I/III, decorin, and tissue inhibitors of metalloproteinases (TIMPs), while downregulating pro-inflammatory cytokines (TGF-beta1, TNF-alpha, IL-6). It activates integrin-mediated focal adhesion kinase (FAK) signaling, promotes mesenchymal stem cell recruitment to wound sites, and stimulates glycosaminoglycan synthesis for extracellular matrix remodeling. The copper ion serves as a cofactor for lysyl oxidase-mediated collagen cross-linking and superoxide dismutase activity, providing both structural repair and antioxidant functions.

Effects

**Integumentary System (Tier 1 — Human Clinical):** GHK-Cu stimulates collagen I, III, and IV synthesis in human dermal fibroblasts. Clinical studies demonstrate measurable increases in skin thickness, density, and elasticity after 12 weeks of topical application at 1–2% concentrations. Reduces fine lines and photoaging signs. Promotes wound re-epithelialization with faster closure times documented in split-thickness skin graft donor sites. **Musculoskeletal System (Tier 2 — Animal + In Vitro):** Promotes bone marrow mesenchymal stem cell differentiation toward osteoblast lineage. Increases decorin and other proteoglycans critical for tendon and ligament integrity. Copper delivery supports lysyl oxidase activity essential for collagen cross-linking in connective tissue. **Immune & Anti-Inflammatory (Tier 2 — Animal + In Vitro):** Suppresses fibrinogen synthesis and pro-inflammatory cytokines including TGF-beta, TNF-alpha, and IL-6 in wound environments, shifting healing from scarring toward regeneration. Reduces free radical damage via superoxide dismutase induction. **Gene Expression (Tier 2 — Genomic Studies):** Broad Connectivity Map analysis reveals GHK-Cu modulates expression of over 4,000 human genes. Upregulates DNA repair genes (ERCC family), antioxidant genes (SOD, catalase), and ubiquitin/proteasome genes associated with protein quality control. Downregulates genes associated with metastasis and tissue destruction (MMP-2, MMP-9). **Nervous System (Tier 3 — Preclinical):** Animal models suggest neurotrophic effects — promotes nerve outgrowth and may support post-injury neural regeneration. GHK-Cu accumulates in brain tissue and modulates iron metabolism genes relevant to neurodegeneration. **Vascular System (Tier 2 — Animal):** Promotes angiogenesis in wound beds through VEGF upregulation. Attracts endothelial cells and mast cells to injury sites, accelerating granulation tissue formation and vascular remodeling. **Hair Follicle Biology (Tier 2 — In Vitro + Limited Human):** Extends the anagen growth phase of hair follicles. Increases follicular size and proliferation of dermal papilla cells. Copper delivery supports melanogenesis, with anecdotal reports of hair color restoration in graying individuals.

Practitioner Guide

**TOPICAL PROTOCOLS:** • Standard concentration: 0.5–2% GHK-Cu in a suitable vehicle (aqueous serum, hydrogel, or liposomal cream). Higher concentrations (>3%) do not improve outcomes and may cause irritation. • Application frequency: Once to twice daily to clean skin. Morning application pairs well with SPF; evening application allows overnight absorption without UV interference. • Stability: GHK-Cu degrades in the presence of ascorbic acid (vitamin C). Do NOT layer with L-ascorbic acid serums — separate by 12 hours or use on alternating days. Niacinamide, hyaluronic acid, and retinol are compatible. **MICRONEEDLING WITH GHK-Cu (Popular Practitioner Protocol):** • Needle depth: 0.5–1.5 mm depending on treatment area (0.5 mm for forehead/periorbital, 1.0–1.5 mm for cheeks/scars). • Apply GHK-Cu serum (1–2%) immediately after microneedling while channels are open. This is the primary delivery window — channels close within 15–30 minutes. • Frequency: Every 4–6 weeks for anti-aging; every 2–4 weeks for active scar remodeling (limit to 4–6 sessions). • Post-procedure: Apply GHK-Cu serum twice daily for 3–5 days following treatment. Avoid AHAs, retinoids, and direct sun for 72 hours. • Clinical pearl: Many practitioners report microneedling + GHK-Cu produces results comparable to PRP (platelet-rich plasma) facials at lower cost. Some combine the two — PRP first, then GHK-Cu serum layered on top. **INJECTABLE PROTOCOLS:** • Subcutaneous injection: 1–2 mg daily or every other day, reconstituted in bacteriostatic water. Typical course: 4–8 weeks. • Injection sites: Rotate between abdomen and love handles for systemic distribution. For localized healing, some practitioners inject peri-lesionally around wound sites or hair loss areas. • Mesotherapy for hair restoration: 0.5–1 mg GHK-Cu diluted to 1–2 mL, injected in 0.1 mL aliquots across the scalp at 1 cm intervals using a 30–32G needle. Sessions every 2–4 weeks for 6–12 sessions. Best results when combined with microneedling of the scalp. Many practitioners combine GHK-Cu mesotherapy with topical minoxidil and oral finasteride/dutasteride for a multi-modal approach. • Clinical pearl: Injectable GHK-Cu is well-tolerated but stings slightly on injection due to the copper ion. Mixing with a small amount of lidocaine (0.1 mL of 1%) eliminates discomfort for scalp injections. **WOUND HEALING CASE REPORTS & PRACTITIONER OBSERVATIONS:** • Diabetic ulcers: Practitioners report improved granulation tissue and faster epithelialization when GHK-Cu (topical gel 1%) is applied to chronic non-healing wounds as adjunctive therapy. Not a replacement for standard wound care but accelerates timelines. • Post-surgical: Applied to surgical incision sites starting 48–72 hours post-closure (after initial hemostasis), practitioners note less hypertrophic scarring and better cosmetic outcomes. Common protocol: topical GHK-Cu 1% BID for 8–12 weeks. • Burns: Limited but encouraging practitioner reports of faster healing in partial-thickness burns with topical GHK-Cu. **HAIR RESTORATION PROTOCOLS (COMPREHENSIVE):** • Topical-only approach: 2% GHK-Cu serum applied to thinning areas nightly. Massage in for 2–3 minutes. Results typically visible at 3–6 months. Works best for diffuse thinning rather than complete alopecia. • Aggressive stack: GHK-Cu mesotherapy (every 2–4 weeks) + daily topical GHK-Cu + microneedling (1.0–1.5 mm, monthly) + minoxidil (on non-microneedling days). Some practitioners add oral supplements (biotin, saw palmetto). • Clinical pearl: GHK-Cu for hair appears to work best in the early stages of thinning (Norwood II–III, Ludwig I–II). Once follicles are fully miniaturized and fibrosed, response rates drop significantly. Manage patient expectations accordingly. **STORAGE & HANDLING:** • Lyophilized GHK-Cu is stable at room temperature. Reconstituted solution should be refrigerated and used within 4–6 weeks. • Blue-green color of solution is normal (copper complex). Color fading suggests degradation. • Topical formulations: Store away from light and heat. Airless pump bottles preferred over jars to limit oxidation.

Dosing Protocols

skin_rejuvenationbasic tier
Dose
1000mcg
Frequency
Once daily or every other day
Timing
Evening before bedtime
Route
subcutaneous
Cycle
4-12 weeks

Evening dosing aligns with nocturnal skin repair cycles; GH release during sleep synergizes with collagen synthesis promotion from GHK-Cu

anti_agingbasic tier
Dose
2000mcg
Frequency
Once daily or every other day
Timing
Evening before bedtime
Route
subcutaneous
Cycle
4-12 weeks

Higher dose targets systemic anti-aging pathways including gene expression modulation; evening timing supports cellular repair

skin_rejuvenationbasic tier
Frequency
1-2x daily
Timing
Morning and/or evening after cleansing skin
Route
topical
Cycle
8-24 weeks

Topical application delivers GHK-Cu directly to dermal layers; twice daily application maintains local concentration for collagen and elastin synthesis

Contraindications & Cautions

  • hard stop — Pregnancy
    No adequate human safety data for injectable GHK-Cu during pregnancy. Topical cosmetic use has limited data. Growth-promoting and angiogenic properties pose theoretical risk to fetal development.
    Action: Do not use injectable form during pregnancy. Topical cosmetic use: consult physician.
  • hard stop — Breastfeeding
    No data on systemic excretion in breast milk from injectable use. Safety not established during lactation.
    Action: Do not use injectable form while breastfeeding. Topical cosmetic use: consult physician.
  • hard stop — Wilson disease
    GHK-Cu delivers copper systemically. Wilson disease is characterized by defective copper excretion leading to toxic copper accumulation. Exogenous copper administration is contraindicated.
    Action: Do not use in patients with Wilson disease or other copper metabolism disorders.
  • hard stop — Under 18 years of age
    Peptide protocols are not designed for pediatric use.
    Action: Do not provide peptide protocols to individuals under 18.
  • caution — Active cancer
    GHK-Cu promotes angiogenesis, cell proliferation, and tissue remodeling. These mechanisms could theoretically support tumor vascularization and growth.
    Action: Avoid injectable use in patients with active cancer. Consult oncologist before any use.

Evidence

Stacks featuring this peptide

The Post-Surgery Recovery Stack
Muscle Recovery / Injury Healing · intermediate

Comprehensive recovery protocol for post-surgical healing. BPC-157 accelerates wound closure, tendon/ligament repair, and reduces surgical inflammation via VEGF and nitric oxide pathways. TB-500 provides systemic tissue repair and angiogenesis (new blood vessel formation to the surgical site). Thymosin Alpha-1 boosts immune defense during the immunosuppressed post-surgical window — critical for preventing post-op infections. GHK-Cu resets gene expression toward wound healing patterns, stimulates collagen I/III deposition, and the copper ion has direct antimicrobial properties. Four distinct healing mechanisms working simultaneously.

The Full Spectrum Anti-Aging Stack
Anti-Aging / Longevity · advanced

Epithalon (telomerase activation) + GHK-Cu (gene expression reset to youthful patterns) + Humanin (mitochondrial protection) + Thymalin (immune rejuvenation) + NAD+ (cellular energy restoration). Each targets a different hallmark of aging: telomere shortening, altered gene expression, mitochondrial dysfunction, immune decline, and NAD+ depletion.

The Skin Rejuvenation Stack
Skin / Cosmetic · basic

Matrixyl (stimulates collagen I/III/IV production) + Argireline (relaxes expression lines via SNARE complex inhibition) + GHK-Cu (resets skin gene expression toward youthful patterns + copper-driven collagen). Covers all three pillars: collagen building, wrinkle relaxation, and gene-level skin rejuvenation.

GLOW Blend (Skin Rejuvenation Stack)
Skin Health / Anti-Wrinkle · intermediate

The GLOW Blend combines three peptides that work synergistically for skin rejuvenation. GHK-Cu is the primary driver — it stimulates collagen I and III synthesis, glycosaminoglycan production, and activates over 4,000 genes involved in tissue remodeling and repair. BPC-157 supports wound healing, angiogenesis, and tissue protection. TB-500 promotes cell migration and reduces inflammation in skin tissue. Together they create a comprehensive skin renewal protocol addressing collagen loss, inflammation, and cellular turnover.

The Skin Glow Stack (Injectable)
Skin / Cosmetic · advanced

For systemic skin rejuvenation beyond what topicals can achieve. GHK-Cu (copper peptide) resets skin gene expression — upregulating collagen I/III, elastin, decorin, and glycosaminoglycans while downregulating inflammatory and degradation genes. SC injection delivers GHK-Cu systemically rather than relying on limited topical penetration. BPC-157 promotes angiogenesis and tissue repair in the dermal layer. Epithalon activates telomerase in fibroblasts, potentially extending their replicative capacity (skin aging is driven partly by fibroblast senescence). Ipamorelin's nightly GH pulse stimulates skin thickness, hydration, and collagen synthesis — GH's cosmetic effects are well-documented in GH deficiency replacement studies.

Research Summary

**Tier 1 (Human Clinical Evidence):** • Wound healing: Multiple controlled human studies confirm accelerated healing of surgical wounds, skin graft donor sites, and chronic ulcers with topical GHK-Cu. Pickart et al. demonstrated significant increases in wound closure rates and skin density. • Anti-aging skin: Randomized controlled trials show topical GHK-Cu (face creams) improves skin elasticity, firmness, and reduces wrinkle depth comparable to vitamin C and retinoic acid formulations. Published in dermatology journals with consistent effect sizes. • Safety profile: Excellent tolerability in clinical studies. No systemic toxicity reported from topical or injectable use. Copper levels remain within physiological range at therapeutic doses. **Tier 2 (Strong Preclinical + Mechanistic):** • Gene expression: Landmark Broad Institute Connectivity Map study showed GHK modulates 4,000+ genes, with patterns suggesting it "resets" gene expression toward a healthier, more youthful profile. This is the strongest gene-modulation dataset for any peptide. • Hair biology: Dermal papilla cell studies and limited human pilot data support follicular stimulation. More robust RCTs needed but mechanistic rationale is strong. • Bone and connective tissue: Animal models demonstrate increased osteoblast activity, improved fracture healing, and enhanced tendon repair. Lysyl oxidase support via copper delivery is well-established biochemistry. • Neuroprotection: In vitro and animal data suggest potential in neurodegeneration via iron chelation and antioxidant gene upregulation. Early-stage but plausible mechanism. **Tier 3 (Emerging / Theoretical):** • Anti-cancer potential: Gene expression data suggests tumor-suppressor gene upregulation and metastasis gene downregulation. No clinical trials; theoretical extrapolation from genomic data. • COPD/lung repair: Single animal study showed improved lung remodeling with GHK-Cu. Very preliminary. • Systemic anti-aging: The broad gene expression reset hypothesis is compelling but unproven in human longevity outcomes. Correlative, not causal, evidence at this stage.

Build a personalized protocol with GHK-Cu →